

**Medicine summary - pericyazine (to end January 2009)**

			Case Group	Death Outcomes	Sole
Case Count			97	0	41
Reaction Count	Blood and lymphatic system disorders	Splenomegaly	1	0	0
		Eosinophilia	1	0	0
		Leukocytosis	3	0	0
		Neutropenia	1	0	0
		<b>Blood and lymphatic system disorders</b>	<b>6</b>	<b>0</b>	<b>0</b>
	Cardiac disorders	Arrhythmia	1	0	0
		Bradycardia	1	0	0
		Tachycardia	3	0	0
		Atrial fibrillation	1	0	0
		Palpitations	3	0	2
		Myocarditis	1	0	0
		<b>Cardiac disorders</b>	<b>10</b>	<b>0</b>	<b>2</b>
	Ear and labyrinth disorders	Tinnitus	1	0	1
		<b>Ear and labyrinth disorders</b>	<b>1</b>	<b>0</b>	<b>1</b>
	Endocrine disorders	Inappropriate antidiuretic hormone secretion	1	0	0
		<b>Endocrine disorders</b>	<b>1</b>	<b>0</b>	<b>0</b>
	Eye disorders	Retinal disorder	1	0	0
		Oculogyric crisis	1	0	1
		Miosis	1	0	0
		Mydriasis	1	0	0
		Accommodation disorder	1	0	1
		Visual impairment	3	0	0
		<b>Eye disorders</b>	<b>8</b>	<b>0</b>	<b>2</b>
	Gastrointestinal disorders	Dental caries	1	0	0
		Rectal haemorrhage	1	0	0
		Constipation	1	0	0
		Abdominal distension	1	0	1
		Faecal incontinence	1	0	0
		Nausea	2	0	2
		Vomiting	3	0	1
		Intestinal obstruction	1	0	1
		<b>Gastrointestinal disorders</b>	<b>11</b>	<b>0</b>	<b>5</b>
	General disorders and administration site conditions	Hyperthermia	1	0	0
Hypothermia		1	0	0	
Pyrexia		7	0	2	
Fatigue		2	0	1	
Malaise		2	0	0	
Gait disturbance		2	0	1	
Face oedema		1	0	1	
Gravitational oedema		1	0	0	
Oedema peripheral		1	0	1	

**Medicine summary - pericyazine (to end January 2009)**

			Case Group	Death Outcomes	Sole
Reaction Count	General disorders and administration site conditions	Chest pain	1	0	0
		Pain	1	0	0
		Chills	2	0	1
		<b>General disorders and administration site conditions</b>	<b>22</b>	<b>0</b>	<b>7</b>
	Hepatobiliary disorders	Hepatitis cholestatic	1	0	1
		Jaundice	3	0	1
		Hepatic function abnormal	4	0	0
		Hepatitis	1	0	1
		<b>Hepatobiliary disorders</b>	<b>9</b>	<b>0</b>	<b>3</b>
	Infections and infestations	Pneumonia	1	0	1
		Upper respiratory tract infection	1	0	0
		<b>Infections and infestations</b>	<b>2</b>	<b>0</b>	<b>1</b>
	Injury, poisoning and procedural complications	Fall	1	0	0
		<b>Injury, poisoning and procedural complications</b>	<b>1</b>	<b>0</b>	<b>0</b>
	Investigations	Blood creatine phosphokinase increased	3	0	0
		Blood folate abnormal	1	0	0
		Weight increased	1	0	1
		<b>Investigations</b>	<b>5</b>	<b>0</b>	<b>1</b>
	Metabolism and nutrition disorders	Anorexia	1	0	0
		Hypokalaemia	1	0	0
		Hyponatraemia	2	0	0
		Hypoglycaemia	1	0	0
		<b>Metabolism and nutrition disorders</b>	<b>5</b>	<b>0</b>	<b>0</b>
	Musculoskeletal and connective tissue disorders	Arthralgia	1	0	1
		Myalgia	3	0	1
		Musculoskeletal stiffness	1	0	1
		<b>Musculoskeletal and connective tissue disorders</b>	<b>5</b>	<b>0</b>	<b>3</b>
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Myeloproliferative disorder	1	0	0
		<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>	<b>1</b>	<b>0</b>	<b>0</b>
	Nervous system disorders	Amnesia	1	0	1
		Disturbance in attention	2	0	1
		Akathisia	1	0	0
		Extrapyramidal disorder	7	0	4
Hyperkinesia		2	0	2	
Hypokinesia		1	0	0	
Tardive dyskinesia		3	0	0	
Dystonia		3	0	1	
Parkinsonism		1	0	1	
Tremor		3	0	1	
Hyperreflexia		2	0	0	

**Medicine summary - pericyazine (to end January 2009)**

			Case Group	Death Outcomes	Sole
Reaction Count	Nervous system disorders	Ataxia	2	0	1
		Coordination abnormal	1	0	0
		Coma	3	0	0
		Consciousness fluctuating	1	0	1
		Somnolence	6	0	2
		Syncope	3	0	3
		Dizziness	5	0	2
		Unresponsive to stimuli	1	0	0
		Visual field defect	1	0	0
		Hypertonia	10	0	3
		Neuroleptic malignant syndrome	13	0	1
		Serotonin syndrome	3	0	0
		Convulsion	2	0	1
		<b>Nervous system disorders</b>	<b>77</b>	<b>0</b>	<b>25</b>
		Psychiatric disorders	Agitation	4	0
	Neurosis		2	0	0
	Confusional state		5	0	0
	Delirium		2	0	1
	Depression		1	0	0
	Depersonalisation		1	0	1
	Delusion		1	0	1
	Hallucination		6	0	2
	Hallucination, visual		1	0	0
	Thinking abnormal		2	0	1
	Mania		1	0	0
	Apathy		2	0	2
	Personality change		1	0	0
	Premature ejaculation		1	0	0
	Libido decreased		1	0	0
	Insomnia		3	0	1
	Nightmare		1	0	1
	Suicide attempt		1	0	0
	<b>Psychiatric disorders</b>		<b>36</b>	<b>0</b>	<b>10</b>
	Renal and urinary disorders		Renal failure	1	0
		Renal impairment	2	0	0
		Urinary incontinence	2	0	2
		Urinary retention	1	0	0
		<b>Renal and urinary disorders</b>	<b>6</b>	<b>0</b>	<b>2</b>
	Reproductive system and breast disorders	Prostatic disorder	1	0	1
		Erectile dysfunction	1	0	0
		Priapism	1	0	1
		Retrograde ejaculation	1	0	1

**Medicine summary - pericyazine (to end January 2009)**

			Case Group	Death Outcomes	Sole
Reaction Count	Reproductive system and breast disorders	<b>Reproductive system and breast disorders</b>	4	0	3
	Respiratory, thoracic and mediastinal disorders	Pneumonia aspiration	1	0	0
		Respiratory arrest	1	0	0
		Hypoxia	1	0	0
		<b>Respiratory, thoracic and mediastinal disorders</b>	3	0	0
	Skin and subcutaneous tissue disorders	Urticaria	1	0	1
		Dermatitis bullous	1	0	1
		Rash erythematous	3	0	2
		Pruritus	2	0	1
		Rash	3	0	2
		Rash maculo-papular	4	0	2
		Systemic lupus erythematosus rash	1	0	0
		Alopecia	1	0	0
		Night sweats	1	0	0
		Purpura	1	0	0
		<b>Skin and subcutaneous tissue disorders</b>	18	0	9
	Vascular disorders	Blood pressure fluctuation	1	0	0
		Hypotension	6	0	3
		Orthostatic hypotension	1	0	0
		Flushing	1	0	1
		Hypertension	2	0	1
		<b>Vascular disorders</b>	11	0	5
	<b>Reaction</b>			<b>242</b>	<b>0</b>